Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT).

Trial Profile

Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT).

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2018

At a glance

  • Drugs Belatacept (Primary) ; Ciclosporin
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Acronyms BENEFIT
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 06 Jun 2018 Results presented at the 2018 American Transplant Congress
    • 06 Jun 2018 Results (n=870) assessing the effect of belatacept on the immunogenicity of individual HLA mismatches from BENEFIT and BENEFIT-EXT Trial cohorts presented at the 2018 American Transplant Congress
    • 06 Jun 2018 Results presented at the 2018 American Transplant Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top